Q-omics provides the consensus-scored HKDC1 profile across patient tissues and cancer cell-line models. HKDC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HKDC1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, HKDC1 RNA expression shows 15,914 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where HKDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HKDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HKDC1 survival associations across molecular data types. HKDC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HKDC1 RNA expression–survival associations across cancer types. High HKDC1 expression shows unfavorable associations in ACC, LUSC, LIHC and UVM, but favorable associations in LGG and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for HKDC1 RNA expression.
This table summarizes HKDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HKDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HKDC1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, LIHC, LUAD and KIRC. The HNSC box plot shows higher HKDC1 RNA expression in tumor versus normal tissue (log2 FC = +1.363, t-test p < 0.001).
This table shows molecular features associated with HKDC1 in patient tissues and cancer cell lines. In patient samples, HKDC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HKDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
